{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bydureon&page=2",
    "query": {
      "intervention": "Bydureon",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bydureon&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-15T07:24:27.155Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01269008",
      "title": "Closed Loop System With Pramlintide Versus Exenatide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Medtronic ePID 2.0",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Albert Einstein College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "18 Years to 30 Years"
      },
      "enrollment_count": 13,
      "start_date": "2010-12",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2018-02-20",
      "last_synced_at": "2026-09-15T07:24:27.155Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01269008"
    },
    {
      "nct_id": "NCT00099320",
      "title": "Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "exenatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "21 Years to 75 Years"
      },
      "enrollment_count": 182,
      "start_date": "2004-05",
      "completion_date": "2005-08",
      "has_results": false,
      "last_update_posted_date": "2015-02-23",
      "last_synced_at": "2026-09-15T07:24:27.155Z",
      "location_count": 40,
      "location_summary": "Birmingham, Alabama • La Jolla, California • San Mateo, California + 37 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Mateo",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Spring Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00099320"
    },
    {
      "nct_id": "NCT04379856",
      "title": "Proof of Concept Study in Patients With Short Bowel Syndrome",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Short Bowel Syndrome"
      ],
      "interventions": [
        {
          "name": "NM-002",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "9 Meters Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 12,
      "start_date": "2020-06-23",
      "completion_date": "2020-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-11-20",
      "last_synced_at": "2026-09-15T07:24:27.155Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04379856"
    },
    {
      "nct_id": "NCT00950677",
      "title": "The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Byetta (exenatide)",
          "type": "DRUG"
        },
        {
          "name": "Symlin (pramlintide)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Years to 21 Years"
      },
      "enrollment_count": 16,
      "start_date": "2009-07",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2017-04-24",
      "last_synced_at": "2026-09-15T07:24:27.155Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00950677"
    },
    {
      "nct_id": "NCT05073692",
      "title": "Comparison of Type 2 Diabetes Pharmacotherapy Regimens",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Type 2 Diabetes Mellitus",
        "Cardiovascular Diseases"
      ],
      "interventions": [
        {
          "name": "SU",
          "type": "DRUG"
        },
        {
          "name": "DPP4",
          "type": "DRUG"
        },
        {
          "name": "SGLT2i",
          "type": "DRUG"
        },
        {
          "name": "GLP-1RA",
          "type": "DRUG"
        },
        {
          "name": "SGLT2i or GLP-1RA",
          "type": "DRUG"
        },
        {
          "name": "Linagliptin (DPP4)",
          "type": "DRUG"
        },
        {
          "name": "Exenatide (GLP-1RA)",
          "type": "DRUG"
        },
        {
          "name": "Liraglutide (GLP-1RA)",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin (SGLT2i)",
          "type": "DRUG"
        },
        {
          "name": "Glimepiride (SU)",
          "type": "DRUG"
        },
        {
          "name": "Glipizide (SU)",
          "type": "DRUG"
        },
        {
          "name": "Glimepiride (SU) or Glipizide (SU)",
          "type": "DRUG"
        },
        {
          "name": "SU or DPP4 (excluding saxagliptin and alogliptin)",
          "type": "DRUG"
        },
        {
          "name": "Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kaiser Permanente",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 241981,
      "start_date": "2021-07-01",
      "completion_date": "2025-03-12",
      "has_results": true,
      "last_update_posted_date": "2025-11-21",
      "last_synced_at": "2026-09-15T07:24:27.155Z",
      "location_count": 6,
      "location_summary": "Pasadena, California • Pleasanton, California • Honolulu, Hawaii + 3 more",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Pleasanton",
          "state": "California"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Bloomington",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05073692"
    },
    {
      "nct_id": "NCT02685852",
      "title": "Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hyperinsulinemic Hypoglycemia"
      ],
      "interventions": [
        {
          "name": "Exenatide",
          "type": "DRUG"
        },
        {
          "name": "Acarbose",
          "type": "DRUG"
        },
        {
          "name": "Exenatide Placebo",
          "type": "DRUG"
        },
        {
          "name": "Acarbose Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 11,
      "start_date": "2016-02",
      "completion_date": "2019-07-22",
      "has_results": false,
      "last_update_posted_date": "2021-05-06",
      "last_synced_at": "2026-09-15T07:24:27.155Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02685852"
    },
    {
      "nct_id": "NCT00856609",
      "title": "The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Weight Loss",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Byetta (exenatide)",
          "type": "DRUG"
        },
        {
          "name": "Weight loss",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Metabolic Chamber",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 150,
      "start_date": "2009-03-03",
      "completion_date": "2016-09-19",
      "has_results": true,
      "last_update_posted_date": "2019-06-04",
      "last_synced_at": "2026-09-15T07:24:27.155Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00856609"
    },
    {
      "nct_id": "NCT02641899",
      "title": "Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ITCA 650 20/60 mcg/day",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "Lisinopril",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        },
        {
          "name": "Digoxin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Intarcia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 33,
      "start_date": "2015-12",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2017-01-27",
      "last_synced_at": "2026-09-15T07:24:27.155Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02641899"
    },
    {
      "nct_id": "NCT01104701",
      "title": "A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "exenatide once weekly",
          "type": "DRUG"
        },
        {
          "name": "exenatide once monthly suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2010-05",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2015-08-20",
      "last_synced_at": "2026-09-15T07:24:27.155Z",
      "location_count": 2,
      "location_summary": "Phoenix, Arizona • Lincoln, Nebraska",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01104701"
    },
    {
      "nct_id": "NCT00353834",
      "title": "The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Exenatide",
          "type": "DRUG"
        },
        {
          "name": "Glargine Insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Joslin Diabetes Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 72,
      "start_date": "2006-08",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2018-01-09",
      "last_synced_at": "2026-09-15T07:24:27.155Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00353834"
    }
  ]
}